LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Biologics/Dipyridamole Coated 3D Printed Implants Grow Bone
Biologics

Dipyridamole Coated 3D Printed Implants Grow Bone

August 9, 2018 2 min read Premium comments

Advertisement

Dipyridamole Coated 3D Printed Implants Grow Bone
Source: Journal of Tissue Engineering and Regenerative Medicine and NYU Langone Health
Secondary#bonegraft#tricalciumphosphate

Patients who are missing some bone due to injury or disease have a number of options for treatment. One is a bone graft to replace their missing bone. Another is an autograft, which is using material that comes from the patient’s own body to form a replacement. And the third is an allograft, which is making use of material that comes from a donor.

Researchers at New York University are working on another option—3D printed ceramic implants that will dissolve slowly within the body while at the same time stimulating bone to grow in their place. 3D printing allows scientists to create implants that precisely fit the defects with which they are faced. The implant may also be coated with chemicals that will promote bone growth.

According to the NYU researchers, their ceramic 3D-printed implants closely resemble the shape and composition of real bone. The raw material is beta tricalcium phosphate—a well-known and common bone grafting material which can safely resorb over time. But, and here’s the key difference, the implant is coated with dipyridamole, a blood thinning agent that stimulates bone growth and attracts bone cells to the implant.

“Dipyridamole has proven to be key to the implant’s success,” said study co-investigator Bruce N. Cronstein, M.D., the Dr. Paul R. Esserman Professor of Medicine at NYU School of Medicine, who also serves as the director of the Clinical and Translational Science Institute, and chief of the Division of Translational Medicine at NYU Langone Health.

Cronstein perfected the drug’s use during device testing. “And because the implant is gradually resorbed, the drug is released a little at a time and locally into the bone, not into the whole body, thereby minimizing risks of abnormal bone growth, bleeding, or other side effects.”

The research is published in a paper entitled “Form and Functional Repair of Long Bone Using 3D Printed Bioactive Scaffolds,” in the Journal of Tissue Engineering and Regenerative Medicine. According to the researchers, the animals on whom they tested the 3D bone were able to absorb the implants into their natural bone, healing defects.

“Our three-dimensional scaffold represents the best implant in development because of its ability to regenerate real bone,” said study senior investigator and biomedical engineer Paulo G. Coelho, D.D.S., Ph.D., the Dr. Leonard I. Linkow Professor at NYU Dentistry and a professor of plastic surgery at NYU School of Medicine. “Our latest study results move us closer to clinical trials and potential bone implants for children living with skull deformations since birth, as well as for veterans seeking to repair damaged limbs.”

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy